Company Profile

Pulse Biosciences Inc (AKA: BioElectroMed Corporation~Bio Electro Med Corp~Electroblate Inc~RPN Research~RPN Enterprises~)
Profile last edited on: 12/1/2023      CAGE: 4KLN1      UEI: DNLSA24FU344

Business Identifier: Pulsed electric field technology to treat cancer and skin conditions)
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3957 Point Eden Way
Hayward, CA 94545
   (510) 906-4600
Location: Single
Congr. District: 14
County: Alameda

Public Profile

Originally named RPN Reesarch, BioElectroMed was acquired by Pulse Biosciences on November 2014. The transaction appears also to have involved two other small firms - ThelioPulse & NanoBlate. In May 2016, Pulse Biosciences successful completed an IPO putting the firm on NASDAQ (PLSE). Building out on technology deeloped at Old Dominionand Universityof Southern California, Pulse Biosciences, Inc. is a clinical-stage medical device company using a platform technology called Nano-Pulse stimulating (NPS). NPS is a non-thermal, precise, focal drug-free electroceutical treatment technology that initiates cell deat. NPS provides treatment in a range of immuno-oncology, dermatology and aesthetic applications offering treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret's esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing PulseTx system (PulseTx), a system for the delivery of NPS treatments. The PulseTx system delivers NPS pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 2 NIH $2,633,620
Project Title: Endopulse System For Endoscopic Ultrasound-Guided Therapy Of Pancreatic Carcinoma
2011 2 NIH $1,895,836
Project Title: Development Of A Nanosecond Pulsed Electric Field System To Treat Skin Cancer
2008 2 NIH $1,952,480
Project Title: Development of an electrical diagnostic for melanoma
2005 2 NIH $1,423,938
Project Title: Development of Bioelectric Field Imaging Instrumentation

Key People / Management

  Pamela Nuccitelli -- President

  Richard L Nuccitelli -- Chief Science Officer